ESSA Pharma Inc
EPIX0.201USD
0.000
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
8.93MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über ESSA Pharma Inc Unternehmen
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
ESSA Pharma Inc Informationen
BörsenkürzelEPIX
Name des UnternehmensESSA Pharma Inc
IPO-datumFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Anzahl der mitarbeiter35
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 22
Addresse999 West Broadway, Suite 720
StadtVANCOUVER
BörseNASDAQ Capital Market Consolidated
LandCanada
PostleitzahlV5Z 1K5
Telefon17783310962
Websitehttps://www.essapharma.com/
BörsenkürzelEPIX
IPO-datumFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Führungskräfte von ESSA Pharma Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Oct 17
Aktualisiert: Fri, Oct 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Xeno Acquisition Corp
100.00%
Opaleye Management Inc.
4.67%
BofA Global Research (US)
1.33%
Aldebaran Capital, LLC
1.22%
Aguja Capital GmbH
1.06%
Aktionäre
Aktionäre
Anteil
Xeno Acquisition Corp
100.00%
Opaleye Management Inc.
4.67%
BofA Global Research (US)
1.33%
Aldebaran Capital, LLC
1.22%
Aguja Capital GmbH
1.06%
Aktionärstypen
Aktionäre
Anteil
Corporation
100.00%
Hedge Fund
7.44%
Investment Advisor
2.79%
Research Firm
2.61%
Venture Capital
0.09%
Investment Advisor/Hedge Fund
0.08%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
79
34.87M
73.70%
-13.44M
2025Q2
91
32.28M
72.72%
-18.24M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Opaleye Management Inc.
2.21M
4.67%
--
--
Jun 30, 2025
BofA Global Research (US)
627.93K
1.33%
-70.34K
-10.07%
Jun 30, 2025
Aldebaran Capital, LLC
578.94K
1.22%
+9.64K
+1.69%
Jun 30, 2025
Aguja Capital GmbH
500.00K
1.06%
--
--
Apr 30, 2025
Two Sigma Investments, LP
483.13K
1.02%
-72.09K
-12.98%
Jun 30, 2025
DLD Asset Management, LP
314.97K
0.67%
+131.31K
+71.50%
Jun 30, 2025
BNP Paribas Securities Corp. North America
271.19K
0.57%
+35.79K
+15.21%
Jun 30, 2025
LMR Partners LLP
200.00K
0.42%
+200.00K
--
Jun 30, 2025
J.P. Morgan Securities LLC
189.07K
0.4%
+24.22K
+14.69%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Oct 6
Aktualisiert: Mon, Oct 6
Name
Anteil
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
